This article presents a microcosting analysis of resources needed for the implementation and sustainment of the Massachusetts model evaluated in the PROUD trial.
Kai Yeung, PharmD, PhD
Advertisement
Articles by Kai Yeung, PharmD, PhD
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5